Health and Innovation: Elderly Fitness, Corporate Battles, and Medical Advances
Recent developments in the health sector include fitness classes helping Ugandan women fight noncommunicable diseases, Humana's legal challenge to US Medicare star ratings downgrades, Sarepta pausing Elevidys gene therapy shipments due to safety concerns, and Fleury's shares rising amid acquisition talks by Rede D'Or.

Elderly women in a Ugandan village are embracing fitness classes to combat rising rates of obesity, diabetes, and other noncommunicable diseases. Clad in traditional attire, the women jog and exercise together, forming a vital part of a community initiative that has enrolled over 1,000 participants in five years.
Humana has launched a new lawsuit, following a dismissal based on technicalities, to contest the U.S. government's lowering of its Medicare star ratings. The Fort Worth, Texas-based case argues that reduced ratings may diminish Humana's customer base and lead to a loss of billions in government bonuses.
Sarepta Therapeutics will cease shipments of its Elevidys gene therapy in response to the deaths of two teenagers from liver failure. The FDA requested the halt due to the incidents related to the treatment for Duchenne muscular dystrophy, prompting the company to comply.
Brazil's medical diagnostics firm Fleury saw its stock surge over 15% amid reports of potential acquisition talks with Rede D'Or. Analysts predict that the merger with the hospital chain could create synergies, amidst a broader trend of consolidation in the Brazilian healthcare market.
(With inputs from agencies.)
- READ MORE ON:
- health
- fitness
- Uganda
- medicare
- Humana
- Sarepta
- gene therapy
- Fleury
- Rede D'Or
- acquisition
ALSO READ
Sarepta Defies FDA Order Amidst Gene Therapy Controversies
Humana Battles Medicare Star Ratings in Federal Court
Sarepta Halts Elevidys Gene Therapy Shipments
Scrutiny Intensified: FDA Calls Halt on Sarepta's Gene Therapy Amid Safety Concerns
Sarepta Therapeutics Temporarily Halts Elevidys Shipments in Compliance with FDA Requests